Healthcare, Regulatory and Reimbursement Landscape - Israel

145pages

Published Date: December 2012

Published By: GlobalData

Category: Healthcare
Description


Healthcare, Regulatory and Reimbursement Landscape Israel

Summary

GlobalData, the industry analysis specialist, has released its latest report, Healthcare, Regulatory and Reimbursement Landscape Israel. An essential source of information and analysis on the Israeli healthcare, regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2011, Israels population was 7.8 million, largely due to a positive balance between the birth rate and mortality rate. The mortality rate is declining due to improvements to healthcare infrastructure and medical and diagnostic services. The pharmaceutical market was estimated to be worth $1.78 billion in 2010 and is expected to reach $2.3 billion by 2020 at a projected Compound Annual Growth Rate (CAGR) of 2.3%. The medical device market was worth approximately $1.2 billion in 2011 and is expected to reach $1.9 billion by 2020 at a CAGR of 4.8%.

These positive trends in Israels healthcare market can primarily be attributed to 
Growing awareness of health and well-being in society
Competitive generic market
Increasing availability of medicines

Scope

  • The report provides information on Israels healthcare, regulatory and reimbursement landscape, including 
  • Overview of the pharmaceutical and medical device markets, including size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical and medical device markets. The key players covered for the pharmaceutical market are Teva, Taro, Dexcel and Rekah, and the key players covered for the medical device market are Medtronic, Boston Scientific Corporation, Siemens Healthcare, B. Braun Melsungen and F. Hoffmann-La Roche.
  • Insightful review of the reimbursement and regulatory landscape, with details of the reimbursement process, regulatory agencies and market authorization processes for new drug and medical devices
  • Detailed analysis of Israels political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the healthcare market

Reasons to buy

The report will enhance your decision-making capability and allow you to 
  • Develop business strategies by understanding the trends shaping and driving the healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnerships
  • Identify, understand and capitalize on the opportunities and challenges in the healthcare market

 

 

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7

2 Introduction 9
2.1 Report Guidance 9

3 Overview of Pharmaceutical and Medical Device Markets 10
3.1 Pharmaceutical Market 10
3.1.1 Overview of Pharmaceutical Market 10
3.1.2 Market Segment 13
3.1.3 Major Disease Areas 14
3.1.4 Major Players 15
3.2 Medical Device Market 30
3.2.1 Market Overview 30
3.2.2 Overview of the Top Five Segments 32
3.2.3 Major Players 43
3.3 Market Drivers and Barriers 61
3.3.1 Drivers 61
3.3.2 Barriers 62

4 Market Access 63
4.1 Reimbursement and Payer Landscape 63
4.1.1 Reimbursement Process 63
4.1.2 Overview of Insurance Providers 65
4.1.3 Drug Price Trend 68
4.1.4 Pricing Policies 69
4.2 Regulatory Landscape 70
4.2.1 Overview of Regulatory Agencies 70
4.2.2 New Drug Approval Process 72
4.2.3 Licensing Process for Pharmaceutical and Medical Device Manufacturing 72
4.2.4 Licensing Process for Pharmaceutical Exports and Imports 73
4.2.5 Intellectual Property Rights 74
4.2.6 Clinical Trial Regulations 75
4.2.7 Pharmaceutical and Medical Devices Advertising Regulations 76
4.2.8 Labeling and Packaging Regulations 77

5 Country Analysis 78
5.1 Political Environment 78
5.1.1 Political Structure 78
5.1.2 Analysis of Current Political Environment 79
5.1.3 Healthcare Policy Initiatives 80
5.2 Economic Landscape 81
5.3 Economic Indicators 82
5.3.1 Gross Domestic Product 82
5.3.2 Gross National Income 86
5.3.3 Inflation 87
5.3.4 Currency Exchange Rate 90
5.3.5 Foreign Direct Investment 91
5.3.6 Foreign Exchange Reserves 92
5.3.7 Trade Balance 93
5.3.8 Government Structural Balance 95
5.3.9 Government Net Debt 96
5.3.10 Major Industries 98
5.4 Demography 99
5.4.1 Population 99
5.4.2 Education and Literacy 114
5.4.3 Employment 116
5.4.4 Disease Burden 117
5.4.5 Healthcare Facilities 119
5.4.6 Healthcare Parameters 123
5.4.7 Healthcare Personnel 124
5.4.8 Environmental Health 128
5.5 Healthcare Expenditure 131
5.5.1 Major Components of Healthcare Spending 132
5.5.2 Share of Public and Private Sector in Healthcare 133
5.5.3 Healthcare Expenditure by Financing Agent 134
5.5.4 Spending in Science and Technology R&D 135
5.6 Trade Associations 136
5.6.1 Pharmaceutical Association of Israel 136
5.6.2 Pharma Israel 136
5.7 Trade Fairs 137

6 Opportunities and Challenges 138
6.1 Opportunities 138
6.2 Challenges 139

7 Appendix 140
7.1 Abbreviations 140
7.2 Bibliography 141
7.3 Methodology 144
7.3.1 Coverage 144
7.3.2 Secondary Research 144
7.3.3 Forecasting 144
7.3.4 Primary Research 145
7.3.5 Expert Panel Validation 145
7.4 Contact Us 145
7.5 Disclaimer 145


List Of Figures


Figure 1: Pharmaceutical Market, Israel, Revenue ($bn), 2005-2010 11
Figure 2: Pharmaceutical Market, Israel, Revenue, Forecast ($bn), 2011-2020 12
Figure 3: Medical Device Market, Israel, Revenue ($m), 2006-2011 30
Figure 4: Medical Device Market, Israel, Revenue Forecast ($m), 2012 --2020 31
Figure 5: Medical Device Market, Israel, Segments, Revenue ($m), 2011 32
Figure 6: Cardiovascular Devices Market, Israel, Revenue ($m), 2006-2011 33
Figure 7: Sales Trends for Major Players*, Cardiovascular Devices, Israel, 2006-2011 34
Figure 8: Nephrology and Urology Devices, Israel, Revenue ($m), 2006-2011 35
Figure 9: Sales Trends for Major Players*, Nephrology and Urology Devices, Israel, 2006-2011 36
Figure 10: In Vitro Diagnostics Market, Israel, Revenue ($m), 2006-2011 37
Figure 11: Sales Trends for Major Players*, In Vitro Diagnostics Devices, Israel, 2006-2010 38
Figure 12: Ophthalmic Devices Market, Israel, Revenue ($m), 2006-2011 39
Figure 13: Sales Trends for Major Players*, Ophthalmic Devices, Israel, 2006-2010 40
Figure 14: Orthopedic Devices Market, Israel, Revenue ($m), 2006-2011 41
Figure 15: Sales Trends for Major Players*, Orthopedic Devices, Israel, 2006-2011 42
Figure 16: Major Medical Device Companies, Israel, Revenues ($m), 2010 43
Figure 17: Drivers and Barriers, Healthcare Market, Israel, 2012 62
Figure 18: Overview of Healthcare System, Israel, 2012 64
Figure 19: Healthcare Spending, Israel, Patient Share (%), 2005-2010 66
Figure 20: Drug Price Trends (%), Israel, 2006-2011 68
Figure 21: Overview of Regulatory Bodies, Israel, 2012 71
Figure 22: GDP Per Capita ($000), Israel, 2006-2011 82
Figure 23: GDP Per Capita ($000), Israel, Forecast, 2012-2020 83
Figure 24: GDP, Annual Growth (%), Israel, 2006-2011 84
Figure 25: GDP, Annual Growth (%), Israel, Forecast, 2012-2020 85
Figure 26: GNI Per Capita ($000), Israel, 2006-2011 86
Figure 27: Average Consumer Price Index, Israel, 2006-2011 87
Figure 28: Average Consumer Price Index, Israel, Forecast, 2012-2020 88
Figure 29: Average Consumer Price, Israel, Annual Change (%), 2006-2011 89
Figure 30: Currency Exchange Rate (ILS/$), Israel, 2006-2011 90
Figure 31: Foreign Direct Investment ($bn), Israel, 2006-2011 91
Figure 32: Foreign Exchange Reserves ($bn), Israel, 2006-2011 92
Figure 33: Imports of Goods and Services ($bn), Israel, 2006-2011 93
Figure 34: Exports of Goods and Services ($bn), Israel, 2006-2011 94
Figure 35: General Government Structural Balance ($bn), Israel, 2005-2010 95
Figure 36: General Government Net Debt ($bn), Israel, 2005-2010 96
Figure 37: General Government Net Debt ($bn), Israel, Forecast, 2011-2020 97
Figure 38: Major Industry Sectors, Net Domestic Product ($bn), Israel, 2010 98
Figure 39: Population (000s), Israel, 2006-2011 99
Figure 40: Population (000s), Israel, Forecast, 2012-2020 100
Figure 41: Urban and Rural Population, Israel, Share (%), 2005-2010 101
Figure 42: Age Groups, Israel, Population Distribution (%), 2005-2010 102
Figure 43: Births (Per 1,000 Population), Israel, 2005-2010 103
Figure 44: Births (Per 1,000 Population), Israel, Forecast, 2011-2020 104
Figure 45: Mortality (Per 1,000 Population), Israel, 2006-2011 105
Figure 46: Mortality (Per 1,000 Population), Israel, Forecast, 2012-2020 106
Figure 47: Major Causes of Mortality (Per 100,000 Population), Israel, 2009 107
Figure 48: Infant Mortality (Per 1,000 Live Births), Israel, 2006-2011 108
Figure 49: Immunization Rate for MMR, DPT, Hib, HBV (%), Israel, 2005-2010 109
Figure 50: Major Causes of Male Mortality (Per 100,000 Population), Israel, 2009 110
Figure 51: Major Causes of Female Mortality (Per 10,0000 Population), Israel, 2009 111
Figure 52: Gender Ratio (M/F), Israel, 2005-2010 112
Figure 53: Life Expectancy at Birth (Years), Israel, 2005-2010 113
Figure 54: National Expenditure, Israel, Education and Literacy (% of GDP), 2005-2010 114
Figure 55: National Expenditure, Israel, Level of Education (%), 2007 115
Figure 56: Unemployment Rate (%), Israel, 2005-2010 116
Figure 57: Most Frequently Diagnosed Diseases (000), Israel, 2009 117
Figure 58: Major Diseases, Israel, DALYs (Per 100,000 Population), 2004 118
Figure 59: Total Number of Hospitals, Israel, 2005-2010 119
Figure 60: Public and Private Hospitals, Israel, 2005-2010 120
Figure 61: Types of Hospital, Israel, 2008-2010 121
Figure 62: Long-term Care Hospitals, Israel, 2008-2010 122
Figure 63: Hospital Beds (Per 1,000 Population), Israel, 2005-2010 123
Figure 64: Doctors (Per 1,000 Population), Israel, 2005-2010 124
Figure 65: Dentists (Per 1,000 Population), Israel, 2006-2011 125
Figure 66: Nurses (Per 1,000 Population), Israel, 2006-2011 126
Figure 67: Pharmacists (Per 1,000 Population), Israel, 2006-2011 127
Figure 68: PM10 (g/m3), Israel, 2005-2010 128
Figure 69: CO2 Emissions (000 Tons), Israel, 2005-2010 129
Figure 70: NOx, CO, SOX Emissions (Tons), Israel, 2005-2010 130
Figure 71: Healthcare Expenditure (% of GDP), Israel, 2005-2010 131
Figure 72: Healthcare Expenditure, Israel, Types of Services (%), 2008 132
Figure 73: Healthcare Expenditure, Israel, Public-Private Share (%), 2005-2010 133
Figure 74: Healthcare Expenditure, Israel, Financing Agent (%), 2008 134
Figure 75: R&D Expenditure, Israel, Science and Technology ($bn), 2005-2010 135
Figure 76: Opportunities and Challenges, Healthcare Market, Israel, 2012 139


List Of Tables


Table 1: Pharmaceutical Market, Israel, Revenue ($bn), 2005-2010 11
Table 2: Pharmaceutical Market, Israel, Revenue ($bn), 2011-2020 12
Table 3: Major Biotechnology Companies and Products, 2011 13
Table 4: Major Products, Teva, Global, Revenue ($m), 2011 15
Table 5: Late-stage Pipeline, Teva, 2012 16
Table 6: Major Products, Taro, 2012 20
Table 7: Major Products, Dexcel Pharma, 2012 23
Table 8: Major Products, Rekah Pharmaceutical, 2012 27
Table 9: Medical Device Market, Israel, Revenue ($m), 2006-2011 30
Table 10: Medical Device Market, Israel, Revenue Forecast ($m), 2012-2020 31
Table 11: Medical Device Market, Israel, Segments, Revenue ($m), 2011 32
Table 12: Cardiovascular Devices Market, Israel, Revenue ($m), 2006-2011 33
Table 13: Sales Trends for Major Players*, Cardiovascular Devices, Israel, 2011 34
Table 14: Nephrology and Urology Devices, Israel, Revenue ($m), 2006-2011 35
Table 15: Sales Trends for Major Players*, Nephrology and Urology Devices, Israel, 2011 36
Table 16: In Vitro Diagnostics Market, Israel, Revenue ($m), 2006-2011 37
Table 17: Sales Trends for Major Players*, In Vitro Diagnostics Devices, Israel, 2010 38
Table 18: Ophthalmic Devices Market, Israel, Revenue ($m), 2006-2011 39
Table 19: Sales Trends for Major Players*, Ophthalmic Devices, Israel, 2010 40
Table 20: Orthopedic Devices Market, Israel, Revenue ($m), 2006-2011 41
Table 21: Sales Trends for Major Players*, Orthopedic Devices, Israel, 2011 42
Table 22: Major Medical Device Companies, Israel, Revenues ($m), 2010 43
Table 23: Major Products, Medtronic, Global, Revenue ($m), 2011 44
Table 24: Major Products, Boston, Global, Revenue ($m), 2010 49
Table 25: Major Products, Siemens Healthcare, Revenue ($m), 2012 51
Table 26: Late-stage Pipeline, Siemens Healthcare, 2012 52
Table 27: Major Product Division, B. Braun, Global, Revenue ($m), 2011 55
Table 28: Major Products, Roche, Global Revenues ($m), 2012 58
Table 29: Late-stage Pipeline, Roche, 2012 58
Table 30: Healthcare Spending, Israel, Patient Share (%), 2005-2010 66
Table 31: HMOs, Israel, Co-payment Cap for Chronically Ill Patients (NIS), 2012 66
Table 32: Drug Price Trends (%), Israel, 2006-2011 68
Table 33: HMOs, Israel, Co-payments for Chronically Ill Patients (NIS) (%), 2012 69
Table 34: GDP Per Capita ($000), Israel, 2006-2011 82
Table 35: GDP Per Capita ($000), Israel, Forecast, 2012-2020 83
Table 36: GDP, Annual Growth (%), Israel, 2006-2011 84
Table 37: GDP, Annual Growth (%), Israel, Forecast, 2012-2020 85
Table 38: GNI Per Capita ($000), Israel, 2006-2011 86
Table 39: Average Consumer Price Index, Israel, 2006-2011 87
Table 40: Average Consumer Price Index, Israel, Forecast, 2012-2020 88
Table 41: Average Consumer Price, Israel, Annual Change (%), 2006-2011 89
Table 42: Currency Exchange Rate (NIS/$), Israel, 2006-2011 90
Table 43: Foreign Direct Investment ($bn), Israel, 2006-2011 91
Table 44: Foreign Exchange Reserves ($bn), Israel, 2006-2011 92
Table 45: Imports of Goods and Services ($bn), Israel, 2006-2011 93
Table 46: Exports of Goods and Services ($bn), Israel, 2006-2011 94
Table 47: General Government Structural Balance ($bn), Israel, 2005-2010 95
Table 48: General Government Net Debt ($bn), Israel, 2005-2010 96
Table 49: General Government Net Debt ($bn), Israel, Forecast, 2011-2020 97
Table 50: Major Industry Sectors, Net Domestic Product ($bn), Israel, 2010 98
Table 51: Population (000), Israel, 2006-2011 99
Table 52: Population (000), Israel, Forecast, 2012-2020 100
Table 53: Urban and Rural Population, Israel, Share (%), 2005-2010 101
Table 54: Age Groups, Israel, Population Distribution (%), 2005-2010 102
Table 55: Births (Per 1,000 Population), Israel, 2005-2010 103
Table 56: Births (Per 1,000 Population), Israel, Forecast, 2011-2020 104
Table 57: Mortality (Per 1,000 Population), Israel, 2006-2011 105
Table 58: Mortality (Per 1,000 Population), Israel, Forecast, 2012-2020 106
Table 59: Major Causes of Mortality (Per 100,000 Population), Israel, 2009 107
Table 60: Infant Mortality (Per 1,000 Live Births), Israel, 2006-2011 108
Table 61: Immunization Rate for MMR, DPT, Hib, HBV (%), Israel, 2005-2010 109
Table 62: Major Causes of Male Mortality (Per 10,0000 Population), Israel, 2009 110
Table 63: Major Causes of Female Mortality (Per 100,000 Population), Israel, 2009 111
Table 64: Gender Ratio (M/F), Israel, 2005-2010 112
Table 65: Life Expectancy at Birth (Years), Israel, 2005-2010 113
Table 66: National Expenditure, Israel, Education and Literacy (% of GDP), 2005-2010 114
Table 67: National Expenditure, Israel, Level of Education (%), 2007 115
Table 68: Unemployment Rate (%), Israel, 2005-2010 116
Table 69: Most Frequently Diagnosed Diseases (000), Israel, 2009 117
Table 70: Major Diseases, Israel, DALYs (Per 100,000 Population), 2004 118
Table 71: Total Number of Hospitals, Israel, 2005-2010 119
Table 72: Public and Private Hospitals, Israel, 2005-2010 120
Table 73: Types of Hospital, Israel, 2008-2010 121
Table 74: Long-term Care Hospitals, Israel, 2008-2010 122
Table 75: Hospital Beds (Per 1,000 Population), Israel, 2005-2010 123
Table 76: Doctors (Per 1,000 Population), Israel, 2005-2010 124
Table 77: Dentists (Per 1,000 Population), Israel, 2006-2011 125
Table 78: Nurses (Per 1,000 Population), Israel, 2006-2011 126
Table 79: Pharmacists (Per 1,000 Population), Israel, 2006-2011 127
Table 80: PM10 (g/m3), Israel, 2005-2010 128
Table 81: CO2 Emissions (000 Tons), Israel, 2005-2010 129
Table 82: NOx, CO, SO2 Emissions (Tons), Israel, 2005-2010 130
Table 83: Healthcare Expenditure (% of GDP), Israel, 2005-2010 131
Table 84: Healthcare Expenditure, Israel, Types of Services (%), 2008 132
Table 85: Healthcare Expenditure, Israel, Public-Private Share (%), 2005-2010 133
Table 86: Healthcare Expenditure, Israel, Financing Agent (%), 2008 134
Table 87: R&D Expenditure, Israel, Science and Technology ($bn), 2005-2010 135
Table 88: Major Healthcare Trade Fairs, Israel, 2013-2014 137

More Reports in





» CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia

Healthcare, Regulatory and Reimbursement Landscape  Malaysia. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and ...


» Power Annual Deals Analysis 2013

The report provides detailed information on mergers and acquisitions (M&A), equity/debt offerings, private equity and venture capital (PE/VC) and partnership transactions registered in the power industry in 2013. The report provides detailed comparative data on the number of deals and their value in the past five years, categorized int...


» Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2013

Power Quarterly Deals Analysis: M&A and Investment Trends  Q4 2013 report is an essential source of data and trend analysis on the mergers and acquisitions (M&As) and financings in the power industry. The report provides detailed information on M&As, equity/debt offerings, private equity (PE), venture financing and partnership...


» Solar PV Power in Italy, Market Outlook to 2025, Update 2014 - Capacity, Generation, Levelized Cost of Energy, Equipment Market, Regulations and Company Profiles

Market Outlook to 2025, Update 2014  Capacity, Generation, Levelized Cost of Energy, Equipment Market, Regulations and Company Profiles is the latest report from GlobalData, the industry analysis specialists that offer comprehensive information and understanding of the solar PV market in Italy. The report provides an indepth analysis on gl...


» Biogas Power in Italy, Market Outlook to 2025, Update 2014 - Capacity, Generation, Regulations and Company Profiles

Biogas Power in Italy, Market Outlook to 2025, Update 2014 - Capacity, Generation, Regulations and Company Profiles Summary "Biogas Power in Italy, Market Outlook to 2025, Update 2014 - Capacity, Generation, Regulations and Company Profiles is the latest report from GlobalData, the industry analysis specialists that offer comprehensive informa...


» Unconventional Oil and Gas Quarterly Deals Review, Q4 2013 - North America Remained the Leading Destination for Acquisitions

Unconventional Oil and Gas Quarterly Deals Review, Q4 2013  North America Remained the Leading Destination for Acquisitions report is an essential source of data and trend analysis on mergers and acquisitions (M&As) and financings in the unconventional oil and gas industry. The report provides detailed information on M&As, equity/d...


» Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014

Malignant Pleural Mesothelioma Global Clinical Trials Review, H1, 2014" provides data on the Malignant Pleural Mesothelioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Malignant Pleural Mesothelioma. It includes an overview of the trial numbers and their recruitment status as p...


» Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014

Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Ovarian Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of ...


» Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014

Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site ...


» Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment sta...



Related News

News Aug 10, 2012

Theranostics Imaging Offers Means of Killing Prostate Cancer Cells without Harming Other Healthy Cells

Cancer imaging experts at John Hopkins Cancer Research Center claimed that they have developed a method for finding and killing malignant cells and sparing the healthy ones. The study was conducted on human prostate cancer cells and mice. The met...

News Oct 29, 2012

The Pharmaceutical Industry And Research

In a world in economic crisis, perhaps still unpredictable consequences in terms of its magnitude and duration, we can reflect on the possible consequences of the crisis may have on the pharmaceutical industry, especially its research and develop...

News Oct 9, 2012

A Donation fund for Pharmaceutical Research

The World Health Organization is planning a Kyoto Protocol for health. States should pay research funds to fight neglected diseases worldwide. To lofty goals lacks the World Health Organization (WHO) does not: It plans with the interests ...

News Oct 10, 2012

Allergy to Cold - Symptoms, Treatment and Tips for Everyday Life

Normally enough warm clothing to defy low outdoor temperatures. Who but suffers from an allergy to cold, has much bigger problems to deal with than "just" cold hands and feet. What is an allergy to cold and how it expresses itself ? ...

News Oct 10, 2012

Healthy Grilling Pleasure

More and more people flock to the park to enjoy the sun. And the barbecue season begins slowly: Instead of greasy sausages and potato salad with mayonnaise, we give you tips for calorie conscious and healthy grilling pleasure. Tonigh...

News Oct 10, 2012

Relaxation on Holiday - but how?

Can the earned annual leave to compensate for the hard work of the rest of the year? We need regular timeouts for regeneration? The recreation research has revealed new aspects. Secured is more important than a good holiday exchange of tension an...

News Oct 10, 2012

Stress and stress that: 7.Stress and Burnout

Everyone knows states of exhaustion - if we have spent ourselves, physically sleep after a long run or mentally after an examination or a combination of both, for example, after a long day at work or when the kids are finally in bed at night...

News Oct 10, 2012

Top 10 Tips for Losing Weight

We summarize now the top 10 tips for losing weight together: They are simple and feasible for anyone who wants to lose weight healthy. A tip from the start: Sets not all weight loss tips to and steps at once, otherwise it will be too much at once...

News Oct 10, 2012

What to do about Anorexia at the Age?

Many people who care for your children at home, the problem: In old age, many people to anorexia. To overcome this, you can use various tricks. First, it helps the members with recipes that they delight to know from your childhood. Especially wit...


All Rights Reserved   Latest News   Latest Reports